Screening for pancreatic cancer in individuals with specific genetic mutations
Pilot Study of Pancreatic Cancer Screening
This study is testing how often routine scans find problems in people with certain genetic mutations linked to breast cancer to see if regular check-ups can help catch pancreatic cancer early.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 250 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of California, San Francisco Academic / other |
| Locations | 1 site (San Francisco, California) |
| Trial ID | NCT05058846 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the frequency of abnormal findings from routine magnetic resonance imaging (MRI) and endoscopic ultrasound (EUS) in individuals with genetic mutations associated with breast cancer, specifically BRCA, ATM, and PALB2. Participants will be divided into two groups based on their family history of pancreatic cancer, with one group undergoing annual imaging and the other completing questionnaires and providing biospecimens over a 10-year period. The study aims to assess the rates of high-grade pancreatic neoplasia precursors and pancreatic ductal adenocarcinoma, as well as to explore participants' attitudes towards screening.
Who should consider this trial
Good fit: Ideal candidates include individuals aged 50 and older with specific genetic mutations and no strong family history of pancreatic cancer, or those aged 18 and older with a strong family history of the disease.
Not a fit: Patients with prior or active pancreatic cancer or those who are pregnant will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance early detection and screening strategies for pancreatic cancer in high-risk individuals.
How similar studies have performed: Other studies have shown promise in using genetic screening for early detection of pancreatic cancer, making this approach both relevant and potentially impactful.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Ability to provide consent and willing, and able to comply with study procedures Ability to read and speak English GROUP I: * Documentation of pathogenic or likely pathogenic germline BRCA 1 and 2, ATM or PALB2 germline genetic mutation * No strong family history of pancreatic cancer (defined as having \>= 1 first-degree or second-degree relative with a history of pancreatic cancer) * Age \>= 50 years old at time of consent. GROUP II: * Documentation of pathogenic or likely pathogenic germline BRCA 1 and 2, ATM, or PALB2 germline genetic mutation * Has strong family history of pancreatic cancer (defined as having \>= 1 first-degree or second-degree relative with a history of pancreatic cancer) * Age \>= 18 years old at time of consent (screening generally begins 10 years prior to the earliest pancreatic cancer in the family) Exclusion Criteria: * Prior or active pancreatic cancer. * Pregnant women are excluded from this study because effects of an MRI on developing fetus is unknown.
Where this trial is running
San Francisco, California
- University of California San Francisco — San Francisco, California, United States (Recruiting)
Study contacts
- Principal investigator: Pamela N Munster, MD — University of California, San Francisco
- Study coordinator: Phu Lam
- Email: Phu.Lam@ucsf.edu
- Phone: (415) 353-8337
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.